Earnings release
Page 1
ASX:NSB +61 8 6268 2641 ir@neuroscientific.com Level 4, 216 St Georges Terrace, PERTH, WA, AUSTRALIA, 6000 ASX Announcement 27 October 2026 Quarterly Activities Report for the Period Ended 30 September 2026 Highlights • Regulatory Engagement (US FDA Pre-IND Meeting): United States Food and Drug Administration (FDA) held a Pre-Investigational New Drug (Pre-IND) meeting to review NSB’s planned Phase 2 clinical trial of StemSmart™ in refractory Crohn's disease, with positive feedback received and announced, subsequent to the reporting period. • Clinical Trial Partner Selected: Subsequent to the quarter end, on 1 October 2026, NSB appointed Southern Star Research to conduct its planned Phase 2 clinical trial for refractory Crohn's disease in Australia and the United States. Trial initiation is targeted by the end of calendar year 2026. • StemSmart™ Technology Transfer: Technology transfer for the manufacturing process for StemSmart™ to Australia-based Q-Gen continued to progress, including conducting engineering runs which provide manufacturing and testing data for review by the Australian Therapeutic Goods Administration (TGA) during their licensure inspection scheduled for October 2026. • Scientific Community Engagement: Chief Medical Officer, Dr Catherine Cole, presented on the StemSmart™ technology platform at the International Society for Cell & Gene Therapy (ISCT) ANZ Conference for 2026, showcasing the technology’s manufacturing process, and the clinical outcomes from its use to date. • Proposed Company Name & Auditor Change: Shareholders approved the change of the Company’s name to Miro Sciences Limited (proposed ASX ticker code “MSX”), which will become effective on Wednesday 28 October 2026. In.Corp Audit & Assurance were appointed as the Company’s new auditor. NeuroScientific Biopharmaceuticals Limited (ASX:NSB) (“NeuroScientific”, “NSB” or the “Company”), an innovative Australian biotechnology company developing novel technologies targeted at immune - mediated inflammatory diseases, is pleased to provide a Quarterly Activities Report and Appendix 4C for the period ended 30 September 2026 (the “Quarter” or the “Reporting Period”). The Company’s change of name to Miro Sciences Ltd (ASX: MSX) will become effective tomorrow, Wednesday 28 October 2026.
Page 2
+61 8 6268 2641 ir@neuroscientific.com Level 4, 216 St Georges Terrace, PERTH, WA, AUSTRALIA, 6000 Commenting on the activities for the Quarter, NeuroScientific’s CEO, Mr Nathan Smith, stated: “I am delighted in our achievem ents during the quarter , where we focused on delivering operational milestones as we progress towards our Phase 2 clinical trial in refractory Crohn’s disease. The pre- IND meeting with the FDA was a critical regulatory objective of the Company as it reinforces our pre- clinical, clinical and manufacturing strateg ies. The outcome of th e pre-IND meeting confirms the StemSmart™ program meets FDA standards and maximises the potential as a therapy for patients with treatment-resistant Crohn’s disease in a clinical setting. In addition, we have continued the transfer of the manufacturing process to Q -Gen as we prepare for the upcoming TGA inspection , another critical operational milestone. Finally, our appointment of Southern Star Research as our clinical trial partner allows us to start the next quarter on a high note as we progress swiftly to initiate the Phase 2 clinical trial by the end of the calendar year.” Overview of Operations During the September 2026 Quarter, the most significant developments for NSB pertained to the ongoing regulatory engagement with the United States Food & Drug Administration (FDA) for the Company’s planned Phase 2 clinical trials relating to StemSmart™, as well as clinical program preparation. U.S. FDA pre-IND Meeting On 13 August 2026, the Company announced that the United States FDA had scheduled its pre- Investigational New Drug (pre-IND) meeting relating to the planned Phase 2 clinical trial targeting refractory Crohn’s disease in both the United States and Australia. As a key regulatory milestone, the pre-IND meeting provides an opportunity for the FDA to provide proactive feedback on prospective treatments and novel drugs, as well as reinforces the anticipated clinical and regulatory milestones meet the standard required to ensure suitability for final IND submission in the future. Commenting on the feedback from the U.S. FDA pre-IND meeting, Chief Medical Officer, Professor Catherine Cole, stated: “The pre-IND meeting with the United States FDA is a critical step towards the initiation of the Phase 2 clinical trial in treatment-resistant Crohn’s disease in the US and Australia. It’s an excellent opportunity to ensure our approach in the design of the trial, the safety profile of the product, and the manufacturing controls are robust and suitable to treat patients in the US. The positive response to our strategy for StemSmart™ from the FDA validates the hard work of our team and the strength of the existing clinical and safety data we have compiled.” Subsequent to the September Quarter’s end, on 13 October 2026, NSB announced it had received positive feedback from the FDA on its planned Phase 2 clinical trial, confirming the proposed design of the trial and receiving favourable responses to 6 out of 7 key questions posed by the Company. The FDA agreed that no additional non-clinical studies would be required due to current weight-of-evidence data in humans previously treated with StemSmart™ being sufficient, and that NSB’s proposed release-testing strategy for StemSmart™ was acceptable for the purposes of the trial. The one outstanding matter related to the StemSmart™ manufacturing testing strategy, which is being implemented by NSB with minimal impact to timelines.
Page 3
+61 8 6268 2641 ir@neuroscientific.com Level 4, 216 St Georges Terrace, PERTH, WA, AUSTRALIA, 6000 Phase 2 Clinical Trial Programs Importantly, NeuroScientific continued with its preparation for its planned Phase 2 clinical trial programs targeting treatment-resistant Crohn’s disease using its proprietary StemSmart™ technology. NSB is on track with initiation of the Phase 2 clinical trial for refractory Crohn’s disease in Australia and the US by the end of CY 2026. In parallel, NSB continues to progress development of an open-label early phase clinical trial in fistulising Crohn’s. Plans for this trial are still being determined, as it may be conducted as a stand-alone trial or in collaboration with leading investigators and research institutions. Manufacturing Technology Transfer – Q-Gen Cell Therapeutics As previously disclosed, NeuroScientific is conducting a technology transfer of the StemSmart™ manufacturing process to Q-Gen Cell Therapeutics (“Q-Gen”), which continued throughout the September Quarter, with the full transfer program remaining on schedule for completion in 2H CY2026 (subject to successful validation and TGA audit). The technology transfer process is currently in its validation phase, with key activities including GMP engineering and demonstration runs of the StemSmart™ product, as well as qualification of the testing and control strategy. The data generated during these activities will be assessed by the TGA during their planned inspection in October 2026, for extension of Q-Gen’s TGA licence to include manufacturing and supply of the StemSmart™ product for NSB’s Phase 2 clinical trials and beyond.
Page 4
+61 8 6268 2641 ir@neuroscientific.com Level 4, 216 St Georges Terrace, PERTH, WA, AUSTRALIA, 6000 Engagement with the Scientific Community During the September Quarter, NSB engaged in key activities relating to its StemSmart™ technology’s functional roles and processes as a therapeutic for inflammatory conditions like Crohn’s Disease. These activities included attendance of the ISCT ANZ 2026 and Australian Gastroenterology Week 2026 Conferences, along with engagement with key clinicians in inflammatory bowel disease and lung disorders. ISCT ANZ 2026 Conference NeuroScientific’s Chief Medical Officer, Dr Catherine Cole, presented an overview of the StemSmart™ technology at the ISCT ANZ 2026 conference in July of 2026, including a biological overview of mesenchymal stem cells (MSCs), the manufacturing process for StemSmart™ originating from bone marrow aspirate collection, as well as the therapeutic’s early clinical data and Special Access Scheme outcomes that demonstrated a “Clinical Response” including for patients with fistulising Crohn’s disease1. CORPORATE Appointment of Auditor On 4 September 2026, NeuroScientific notified shareholders that Horizon Nexus (WA) Audit Pty Ltd had resigned as the Company’s auditor, and that In.Corp Audit & Assurance Pty Ltd had been appointed as the Company’s new auditor (subject to shareholder approval at NSB’s Annual General Meeting, which was received on 15 October 2026). Name Change Approval to change the Company’s name to “Miro Sciences Ltd” (ASX ticker code “MSX”) was obtained on 15 October 2026. The change of name aligns the Company’s identity with its new strategic direction following the acquisition of StemSmart™. Financial September Quarter Cash Flows As at 30 September 2026, NeuroScientific reported a cash balance of $3.9 million. For the September Quarter, NeuroScientific reported net cash used for operating activities of $719k, with expenditure for the Reporting Period primarily used for research and development work ($409k) of which $49k related to the technology transfer with Q-Gen. Staff costs not classified within research and development were approximately $69k, administration and corporate costs were approximately $242k. Related Party Payments In accordance with ASX Listing Rule 4.7C.3 for related party payments, the Quarter included payments of $80k relating to Director fees, salaries and superannuation.
Page 5
+61 8 6268 2641 ir@neuroscientific.com Level 4, 216 St Georges Terrace, PERTH, WA, AUSTRALIA, 6000 Outlook for NeuroScientific Biopharmaceuticals As NeuroScientific enters the 2027 Financial Year with its momentum towards Phase 2 clinical trials for StemSmart™ and off the back of the successful treatment of fistulising Crohn’s disease patients under SAS1, key anticipated milestones for the Company include: • Completion of the StemSmart™ technology transfer to Q-Gen Cell Therapeutics, including regulatory audit with the TGA and Q-Gen’s licence expansion, anticipated before the end of the calendar year. • Finalisation of clinical trial preparation and protocols pertaining to the refractory Crohn’s Disease program (Australia and U.S.) taking place in 2H of CY2026. • Ongoing clinical development of the fistulising Crohn’s program supported by SAS results. • Continued engagement with regulatory and clinical stakeholders, as well as investors and the public surrounding updates for the Phase 2 clinical trial work for StemSmart™ programs. • Regarding strategic options for EmtinB™, the Company will continue to actively pursue out- licensing and strategic partnership opportunities for the asset. StemSmart™ Key Addressable Markets2 • Crohn’s Disease: Global market US$13.8 billion by 2026; • Kidney Transplant: Global market for organ transplant immuno-suppressants, increasing to US$7.2 billion by 2030 (majority for renal); • Lung Disorders: Global market US$33 billion by 2034; and • GvHD: Global market increasing to US$5.31 billion in 2032. 1 ASX Announcement (26 May 2026) – “Remarkable Results from Patients Treated with StemSmart under Special Access Program” 2 ASX Announcement (27 June 2025) – “StemSmart Acquisition Complete” This announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Limited. For more information, please contact: Nathan Smith Chief Executive Officer NeuroScientific Biopharmaceuticals Ltd ir@neuroscientific.com Jane Morgan Investor & Media Relations Jane Morgan Management jm@janemorganmanagement.com.au
Page 6
+61 8 6268 2641 ir@neuroscientific.com Level 4, 216 St Georges Terrace, PERTH, WA, AUSTRALIA, 6000 About NeuroScientific Biopharmaceuticals Ltd NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a biotechnology company focused on the development of novel therapeutics targeting immune-mediated inflammatory disorders. The Company’s research is centred on modulating pathological immune responses involved in chronic and degenerative conditions, particularly where current therapeutic options demonstrate limited efficacy or durability. NSB applies advanced preclinical and translational strategies to support the development of first-in-class or best-in-class biologics addressing significant unmet clinical need. Targeting Crohn’s Disease with StemSmart™ Technology Following the acquisition of Isopogen WA Ltd, NSB is prioritizing the application of its proprietary StemSmart technology targeting fistulising Crohn’s disease—a severe and treatment-resistant form of the condition. NSB’s StemSmart™ product is derived from adult human donor bone marrow-sourced MSCs that is produced using a patented manufacturing process developed at Royal Perth Hospital, Western Australia and designed to improve therapeutic activity and clinical response. Following the successful treatment of fistulising Crohn’s disease patients under SAS , the Company intends to conduct a Phase 2 clinical trial to further evaluate safety and preliminary efficacy in refractory and/or fistulising Crohn’s disease. This initiative aligns with NSB’s broader strategy to obtain regulatory and reimbursement approval for its MSC therapy both in Australia and internationally, with the goal of making the treatment available to patients with fistulising and refractory Crohn’s disease, for whom current therapies remain inadequate. About EmtinB™ EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body’s innate immune response to cell injury. Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations. Forward Looking Statements This announcement may contain certain “forward-looking statements”. Forward looking statements can generally be identified by the use of forward-looking words such as, “expect”, “should”, “could”, “may”, “predict”, “plan”, “will”, “believe”, “forecast”, “estimate”, “target” and other similar expressions. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. You are strongly cautioned not to place undue reliance on forward looking statements, including in respect of the financial or operating outlook for the Company. Except as required by law or any relevant listing rules of the ASX, the Company assumes no obligation to provide any additional or updated information or to update any forward-looking statements, whether as a result of new information, future events or results, or otherwise. Nothing in this announcement will, under any circumstances (including by reason of this announcement remaining available and not being superseded or replaced by any other presentation or publication with respect to the Company, or the subject matter of this announcement), create an implication that there has been no change in the affairs of the Company since the date of this announcement.
Page 7
Rule 4.7B ASX Listing Rules Appendix 4C (17/07/20) Page 1 + See chapter 19 of the ASX Listing Rules for defined terms. Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Name of entity NeuroScientific Biopharmaceuticals Limited ABN Quarter ended (“current quarter”) 13 102 832 995 30 September 2026 Consolidated statement of cash flows Current quarter $A’000 Year to date (3 months) $A’000 1. Cash flows from operating activities - - 1.1 Receipts from customers 1.2 Payments for (409) (409) (a) research and development (b) product manufacturing and operating costs - - (c) advertising and marketing (50) (50) (d) leased assets - - (e) staff costs (69) (69) (f) administration and corporate costs (242) (242) 1.3 Dividends received (see note 3) - - 1.4 Interest received 51 51 1.5 Interest and other costs of finance paid - - 1.6 Income taxes paid - - 1.7 Government grants and tax incentives - - 1.8 Other (provide details if material) - - 1.9 Net cash from / (used in) operating activities (719) (719) 2. Cash flows from investing activities - - 2.1 Payments to acquire or for: (a) entities (b) businesses - - (c) property, plant and equipment - - (d) investments - - (e) intellectual property - - (f) other non-current assets - -
Page 8
Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B ASX Listing Rules Appendix 4C (17/07/20) Page 2 + See chapter 19 of the ASX Listing Rules for defined terms. Consolidated statement of cash flows Current quarter $A’000 Year to date (3 months) $A’000 2.2 Proceeds from disposal of: - - (a) entities (b) businesses - - (c) property, plant and equipment - - (d) investments - - (e) intellectual property - - (f) other non-current assets - - 2.3 Cash flows from loans to other entities - - 2.4 Dividends received (see note 3) - - 2.5 Other (provide details if material) - - 2.6 Net cash from / (used in) investing activities - - 3. Cash flows from financing activities - - - - 3.1 Proceeds from issues of equity securities (excluding convertible debt securities) 3.2 Proceeds from issue of convertible debt securities - - 3.3 Proceeds from exercise of options - - 3.4 Transaction costs related to issues of equity securities or convertible debt securities - - 3.5 Proceeds from borrowings - - 3.6 Repayment of borrowings - - 3.7 Transaction costs related to loans and borrowings - - 3.8 Dividends paid - - 3.9 Other (provide details if material) - - 3.10 Net cash from / (used in) financing activities - - 4. Net increase / (decrease) in cash and cash equivalents for the period 4,630 4,630 4.1 Cash and cash equivalents at beginning of period 4.2 Net cash from / (used in) operating activities (item 1.9 above) (719) (719) 4.3 Net cash from / (used in) investing activities (item 2.6 above) - -
Page 9
Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B ASX Listing Rules Appendix 4C (17/07/20) Page 3 + See chapter 19 of the ASX Listing Rules for defined terms. Consolidated statement of cash flows Current quarter $A’000 Year to date (3 months) $A’000 4.4 Net cash from / (used in) financing activities (item 3.10 above) - - 4.5 Effect of movement in exchange rates on cash held - - 4.6 Cash and cash equivalents at end of period 3,911 3,911 5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts Current quarter $A’000 Previous quarter $A’000 5.1 Bank balances 911 630 5.2 Call deposits 3,000 4,000 5.3 Bank overdrafts - - 5.4 Other (provide details) - - 5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above) 3,911 4,630 6. Payments to related parties of the entity and their associates Current quarter $A'000 6.1 Aggregate amount of payments to related parties and their associates included in item 1 (80) 6.2 Aggregate amount of payments to related parties and their associates included in item 2 - Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments. Item 6.1 above includes Director salaries, fees & superannuation.
Page 10
Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B ASX Listing Rules Appendix 4C (17/07/20) Page 4 + See chapter 19 of the ASX Listing Rules for defined terms. 7. Financing facilities Note: the term “facility’ includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity. Total facility amount at quarter end $A’000 Amount drawn at quarter end $A’000 7.1 Loan facilities - - 7.2 Credit standby arrangements - - 7.3 Other (please specify) - - 7.4 Total financing facilities - - 7.5 Unused financing facilities available at quarter end - 7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. 8. Estimated cash available for future operating activities $A’000 8.1 Net cash from / (used in) operating activities (item 1.9) (719) 8.2 Cash and cash equivalents at quarter end (item 4.6) 3,911 8.3 Unused finance facilities available at quarter end (item 7.5) - 8.4 Total available funding (item 8.2 + item 8.3) 3,911 8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1) 5.44 Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5. 8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions: 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not? Answer: n/a 8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful? Answer: n/a 8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis? Answer: n/a Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
Page 11
Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B ASX Listing Rules Appendix 4C (17/07/20) Page 5 + See chapter 19 of the ASX Listing Rules for defined terms. Compliance statement 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A. 2 This statement gives a true and fair view of the matters disclosed. Date: 27 October 2026 Authorised by: The Board of Directors